Pfizer’s Crizotinib Eases Past FDA With Targeted Population
By
Mary Jo Laffler / Email the Author / “The Pink Sheet” Aug. 29, 2011, Vol. 73, No. 35
New Products / Word Count: 819 / Article # 00110829015
Executive Summary
FDA is showing for the second time in as many weeks that all things are possible when it comes to clearing targeted oncologics with compelling evidence. The agency cleared Pfizer’s Xalkori (crizotinib) for late-stage non-small cell lung cancer Aug. 26, just under five months from submission and based on early stage evidence.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.